Pharmacyclic’s Co-Development Pact With Janssen Carries Largest Single-Asset Upfront Payment Of 2011

By Joseph Haas / Email the Author / “The Pink Sheet” DAILY Dec. 9, 2011
Word Count: 822 / Article # 14111209002

Executive Summary

The two companies will co-develop and co-commercialize PCI-32765, which is being investigated in multiple types of hematological cancer.

Purchase this Article

$50.00 Buy Now

For $50.00, purchase this 822-word article and receive immediate online access. 100% Satisfaction Guarantee.

View a complete sample article »

Already a Subscriber?

Log in for complete access.

Questions?

Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.

Log In

Email Address

Password

Remember Me

Forgot your password?

Don’t Have an Account?

If your employer has a site license, create your account to begin using it. Simply click ‘Create An Account’ button below to register now.

Otherwise, please explore our free content subscriptions.

Create an account

Enter the email address associated with your account and a temporary password will be sent to you.

Email Address

Need help? Contact us at (800) 332-2181, +1 (908) 547-2159, or custcare@elsevier.com

Email Article

* Required field

* To:

For multiple recipients, separate email addresses with a semi-colon.

* Your Name:

* Your Email:

Subject: Pharmacyclic’s Co-Development Pact With Janssen Carries Largest Single-Asset Upfront Payment Of 2011

* Add a personalized message to your email:

Please Note: Only individuals with subscriptions to “The Pink Sheet” DAILY will be able to access the full article. All other readers will be directed to the abstract and may purchase the article.

or Cancel

Pharmacyclic’s Co-Development Pact With Janssen Carries Largest Single-Asset Upfront Payment Of 2011

Executive Summary

Purchase this Article

Already a Subscriber?

Questions?

Related Articles: 8

Elsevier Business Intelligence Publications

Offers & Events

Related Deals: 1

Strategic Transactions

Topics Covered in this Article

Email Article